Bulk Pharmaceutical API Sources for DYLOJECT

Bulk Pharmaceutical API Sources for DYLOJECT

Vendor	Vendor Homepage	Vendor Sku	API Url
Vitas-M Laboratory		STK400073
TCI (Tokyo Chemical Industry)		D2508
Molport		MolPort-000-699-119
Hangzhou APIChem Technology		AC-1487
AKos Consulting & Solutions		AKOS000310014

DYLOJECT API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sources for DYLOJECT, a brand name for the pharmaceutical product containing diclofenac sodium. The analysis focuses on key players, their manufacturing capabilities, geographic distribution, and potential supply chain risks.

What is DYLOJECT and its API?

DYLOJECT is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for the treatment of pain and inflammation. The active pharmaceutical ingredient (API) in DYLOJECT is diclofenac sodium. Diclofenac sodium is a potent analgesic and anti-inflammatory agent that works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Its chemical name is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid sodium salt.

Who are the Primary API Manufacturers for Diclofenac Sodium?

The global market for diclofenac sodium API is characterized by a mix of large, established manufacturers and smaller, specialized producers. Key players identified through patent filings, regulatory approvals, and industry databases include:

• Syngene International Limited: A leading Indian contract research, development, and manufacturing organization (CRDMO). Syngene has a significant presence in API manufacturing, including NSAIDs.
• Divi's Laboratories Limited: Another major Indian API manufacturer with extensive experience in complex chemical synthesis. Divi's is known for its high-volume production capabilities.
• Lupin Limited: A global pharmaceutical company with a strong API division. Lupin produces a wide range of APIs, and diclofenac sodium is among its portfolio.
• Granules India Ltd.: An Indian pharmaceutical company focusing on the development and manufacturing of APIs and finished dosage forms. Granules has demonstrated capacity for diclofenac sodium production.
• Dr. Reddy's Laboratories Ltd.: A multinational pharmaceutical company headquartered in India. Dr. Reddy's is a significant producer of various APIs, including diclofenac sodium.
• IOL Chemicals and Pharmaceuticals Limited: An Indian manufacturer of bulk drugs and specialty chemicals. IOL has a strong focus on APIs for pain management.
• AUROBINDO PHARMA LTD: A vertically integrated pharmaceutical company with substantial API manufacturing operations, particularly in India.
• Alkem Laboratories Ltd.: An Indian pharmaceutical company that manufactures and markets a range of pharmaceutical products, including APIs.
• SANTEN PHARMACEUTICAL CO., LTD.: While primarily known for ophthalmic products, Santen has manufacturing capabilities that may extend to APIs like diclofenac sodium for specific applications or regional markets.
• Farmabios S.p.A.: An Italian API manufacturer that may produce diclofenac sodium, often focusing on niche or high-quality segments.

These manufacturers operate under strict regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

What are the Key Manufacturing Regions for Diclofenac Sodium API?

The manufacturing of diclofenac sodium API is geographically concentrated, with India being the dominant player.

Region	Key Countries
Asia	India, China
Europe	Italy, Germany

India's Dominance in API Production

India holds the largest share of global API manufacturing, including diclofenac sodium. This is attributed to several factors:

• Cost-Effectiveness: Lower labor and operational costs compared to Western countries.
• Skilled Workforce: A large pool of trained chemists and engineers.
• Robust Regulatory Framework: Compliance with international GMP (Good Manufacturing Practice) standards is well-established.
• Government Support: Policies encouraging pharmaceutical manufacturing and exports.

A significant number of the listed key players have their primary manufacturing facilities or significant operations in India.

China's Role in the Supply Chain

China is another major global supplier of APIs. While its market share for diclofenac sodium may be less pronounced than India's, Chinese manufacturers are significant contributors to the global supply chain. Regulatory compliance and quality standards have been areas of increasing focus for Chinese API producers.

European Manufacturers

European manufacturers, such as Farmabios S.p.A., often focus on higher-value APIs, specialized production, or serve regional markets with stringent quality requirements. Their production volumes may be lower but can be critical for specific product formulations or supply chain diversification.

What are the Regulatory Considerations for Diclofenac Sodium API?

The production and supply of diclofenac sodium API are subject to rigorous regulatory requirements to ensure safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines as established by regulatory bodies like the FDA (21 CFR Parts 210 and 211) and the EMA. This ensures consistency in production and quality control.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and facilities. Pharmaceutical companies reference these DMFs in their drug product applications.
• Inspections and Audits: Manufacturing sites are subject to regular inspections by regulatory authorities. Pharmaceutical companies also conduct their own audits of API suppliers to verify compliance and assess risk.
• Impurity Profiling: Strict control and characterization of impurities are essential. Regulatory agencies require detailed information on potential impurities, including genotoxic impurities, and established limits.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide a framework for quality, safety, and efficacy standards that are widely adopted globally.

What are the Potential Supply Chain Risks for Diclofenac Sodium API?

The globalized nature of API manufacturing presents several potential risks that can impact the availability and cost of diclofenac sodium.

Geopolitical and Economic Factors

• Trade Disputes and Tariffs: Changes in international trade policies can affect the cost of raw materials and finished APIs.
• Currency Fluctuations: Volatility in exchange rates can impact the profitability and pricing of APIs sourced internationally.
• Political Instability: Disruptions in countries with significant API manufacturing bases can lead to supply shortages.

Environmental Regulations and Compliance

• Stricter Environmental Standards: Increasingly stringent environmental regulations in major manufacturing hubs like India and China can lead to increased operational costs, temporary shutdowns for compliance upgrades, or relocation of manufacturing. This has been a recurring theme for chemical and API manufacturing in these regions over the past decade [1].
• Waste Management: Proper disposal of chemical waste is a critical and costly aspect of API production.

Quality and Regulatory Issues

• FDA/EMA Actions: Warnings, import alerts, or other enforcement actions by regulatory bodies against API manufacturers can halt supply from specific facilities.
• Recalls and Batch Failures: Quality control failures can lead to product recalls, impacting inventory and brand reputation.
• Intellectual Property Disputes: While diclofenac sodium itself is a well-established generic molecule with expired primary patents, disputes can arise related to manufacturing processes or novel formulations.

Raw Material Sourcing

• Dependency on Precursors: The synthesis of diclofenac sodium relies on specific precursor chemicals. Disruptions in the supply of these raw materials can affect API production.
• Single-Source Suppliers: Over-reliance on a single supplier for critical raw materials increases vulnerability.

Pandemic and Health Crises

• Lockdowns and Travel Restrictions: As seen with COVID-19, global health crises can disrupt manufacturing operations, logistics, and workforce availability.

What are the Commercial and Market Dynamics?

The market for diclofenac sodium API is mature and competitive, driven largely by generic drug manufacturers.

• Price Sensitivity: As a widely used generic API, price is a significant factor in purchasing decisions. Manufacturers with efficient production processes and economies of scale have a competitive advantage.
• Quality and Reliability: Despite price pressures, consistent quality and reliable supply are paramount for pharmaceutical companies seeking to maintain their drug product manufacturing.
• Consolidation: The API sector has seen consolidation, with larger players acquiring smaller ones to expand their product portfolios and market reach.
• Emerging Markets: Growing healthcare demand in emerging economies presents opportunities for increased API consumption.

What are the Key Takeaways?

The global supply chain for diclofenac sodium API is primarily anchored by manufacturers in India, supported by producers in China and Europe. While the market is competitive and price-sensitive, regulatory compliance, quality assurance, and supply chain resilience are critical factors for pharmaceutical companies. Diversification of API sources, robust supplier qualification processes, and proactive risk management are essential for ensuring a stable supply of DYLOJECT. Environmental regulations and geopolitical stability are significant factors influencing manufacturing costs and availability.

Frequently Asked Questions

1. Which countries are the largest producers of diclofenac sodium API?

India is the dominant producer of diclofenac sodium API, followed by China. European countries like Italy also contribute to the global supply.

2. What are the main regulatory requirements for diclofenac sodium API manufacturers?

Manufacturers must adhere to Good Manufacturing Practices (GMP), submit Drug Master Files (DMFs) to regulatory agencies, and undergo regular inspections. Compliance with ICH guidelines is also essential.

3. How does environmental regulation impact diclofenac sodium API production?

Stricter environmental regulations can increase production costs, necessitate facility upgrades, or lead to temporary operational halts to ensure compliance with waste management and pollution control standards.

4. What are the primary risks associated with sourcing diclofenac sodium API from a single country?

Sourcing from a single country creates vulnerability to geopolitical events, trade disputes, natural disasters, or localized regulatory actions that could disrupt the entire supply chain.

5. How can pharmaceutical companies mitigate supply chain risks for diclofenac sodium API?

Mitigation strategies include qualifying multiple suppliers across different geographies, maintaining safety stock, conducting thorough supplier audits, and staying informed about regulatory and geopolitical developments.

Citations

[1] India Ministry of Environment, Forest and Climate Change. (n.d.). Central Pollution Control Board. Retrieved from https://cpcb.nic.in/